Is Johnson & Johnson a Buy?

Johnson & Johnson (NYSE: JNJ) is a blue-chip pharma stock with annual revenues in the neighborhood of $80 billion -- and that's before considering the potential of its coronavirus vaccine candidate, JNJ-78436735. According to an interim data release from its phase 1/2 clinical trial, more than 90% of 805 healthy volunteers who received JNJ-78436735 developed neutralizing antibodies against SARS-CoV-2 by day 29 post-inoculation. Here's the kicker -- the experimental vaccine produced exceptional efficacy after just a single dose.